Progress in Cardiovascular Diseases
Volume 53, Issue 1 , Pages 10-14 , July 2010

The Contribution of the Framingham Heart Study to the Prevention of Cardiovascular Disease: A Global Perspective

  • Shanthi Mendis

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Shanthi Mendis, MBBS, MD, FRCP, FACC, Cardiovascular Diseases, World Health Organization, Geneva, Switzerland.

References 

  1. The global burden of disease: 2004 update. Geneva, Switzerland: World Health Organization, 2008.
  2. Kannel WB, Dawber TR, Kagan A, et al. Factors of risk in the development of coronary heart disease—six year follow-up experience. The Framingham Study. Ann Intern Med. 1961;55:33–50(PubMed ID Number: 13751103: No Abstract)
  3. Kannel WB, Dawber TR, Friedman GD, et al. Risk factors in coronary heart disease; an evaluation of several serum lipids as predictors of coronary heart disease. Ann Intern Med. 1964;61:888–899(PubMed ID Number: 14233810: No Abstract)
  4. Kannel WB, Dawber TR, Thomas HE, et al. Comparison of serum lipids in the prediction of coronary heart disease. Framingham study indicates that cholesterol level and blood pressure are major factors in coronary heart disease; effect of obesity and cigarette smoking also noted. R I Med J. 1965;48:243–250(PubMed ID Number: 14325143: No Abstract)
  5. Kannel WB, Brand N, Skinner JJ, et al. The relation of adiposity to blood pressure and development of hypertension. The Framingham study. Ann Intern Med. 1967;67:48–59(PubMed ID Number: 6028658: no Abstract)
  6. Kannel WB, LeBauer EJ, Dawber TR, et al. Relation of body weight to development of coronary heart disease. The Framingham study. Circulation. 1967;35:734–744(PubMed ID Number: 6024013: No Abstract)
  7. Kannel WB, Castelli WP, McNamara PM. The coronary profile: 12-year follow-up in the Framingham study. J Occup Med. 1967;9:611–619(PubMed ID Number: 6065137: No Abstract)
  8. Kannel WB, Schwartz MJ, McNamara PM. Blood pressure and risk of coronary heart disease: the Framingham study. Dis Chest. 1969;56:43–52(PubMed ID Number: 5789839: No Abstract)
  9. Kannel WB, Castelli WP, Gordon T, et al. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med. 1971;74:1–12(PubMed ID Number: 5539274: No Abstract)
  10. Garcia MJ, McNamara PM, Gordon T, et al. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes. 1974;23:105–111(PubMed ID Number: 4359625: No Abstract)
  11. Haynes SG, Levine S, Scotch N, et al. The relationship of psychosocial factors to coronary heart disease in the Framingham study. I. Methods and risk factors. Am J Epidemiol. 1978;107:362–383(PubMed ID Number: 665654: Abstract)
  12. Haynes SG, Feinleib M, Levine S, et al. The relationship of psychosocial factors to coronary heart disease in the Framingham study. II. Prevalence of coronary heart disease. Am J Epidemiol. 1978;107:384–402(PubMed ID Number: 665655: Abstract)
  13. Kannel WB, Mcgee DL. Diabetes and cardiovascular risk factors: the Framingham study. Circulation. 1979;59:8–13(PubMed ID Number: 758126: Abstract)
  14. Kannel WB, Mcgee D, Gordon T. A general cardiovascular risk profile: the Framingham Study. Am J Cardiol. 1976;38:46–51(PubMed ID Number: 132862: Abstract)
  15. Haynes SG, Feinleib M, Kannel WB. The relationship of psychosocial factors to coronary heart disease in the Framingham Study. III. Eight-year incidence of coronary heart disease. Am J Epidemiol. 1980;111:37–58(PubMed ID Number: 7352459: Abstract)
  16. Castelli WP, Garrison RJ, Dawber TR, et al. The filter cigarette and coronary heart disease: the Framingham study. Lancet. 1981;2:109–113(PubMed ID Number: 6113480: Abstract)
  17. Hubert HB, Feinleib M, McNamara PM, et al. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983;67:968–977(PubMed ID Number: 6219830: Abstract)
  18. Sytkowski PA, Kannel WB, D'Agostino RB. Changes in risk factors and the decline in mortality from cardiovascular disease. the Framingham Heart Study. N Engl J Med. 1990;322:1635–1641(PubMed ID Number: 2288563: Abstract)
  19. Kannel WB. Bishop lecture. Contribution of the Framingham Study to preventive cardiology. J Am Coll Cardiol. 1990;15:206–211(PubMed ID Number: 2136875: No Abstract)
  20. Kannel WB, Wolf PA, Verter J, et al. Epidemiologic assessment of the role of blood pressure in stroke. The Framingham study. JAMA. 1970;214:301–310(PubMed ID Number: 5469069: No Abstract)
  21. Wolf PA, Dawber TR, Thomas HE, et al. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology. 1978;28:973–977(PubMed ID Number: 570666: Abstract)
  22. Kannel WB, Gordon T, Offutt D. Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence, and mortality in the Framingham study. Ann Intern Med. 1969;71:89–105(PubMed ID Number: 4239887: No Abstract)
  23. Kannel WB, McNamara PM, Feinleib M, et al. The unrecognized myocardial infarction. Fourteen-year follow-up experience in the Framingham study. Geriatrics. 1970;25:75–87(PubMed ID Number: 5411048: No Abstract)
  24. Kannel WB, Gordon T, Castelli WP, et al. Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease. The Framingham study. Ann Intern Med. 1970;72:813–822(PubMed ID Number: 4247338: No Abstract)
  25. Mckee PA, Castelli WP, McNamara PM, et al. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971;285:1441–1446(PubMed ID Number: 5122894: No Abstract)
  26. Kannel WB, Gordon T, Schwartz MJ. Systolic versus diastolic blood pressure and risk of coronary heart disease. The Framingham study. Am J Cardiol. 1971;27:335–346(PubMed ID Number: 5572576: No Abstract)
  27. Gordon T, Kannel WB. Premature mortality from coronary heart disease. The Framingham study. JAMA. 1971;215:1617–1625(PubMed ID Number: 5107681: No Abstract)
  28. Kannel WB, Castelli WP, McNamara PM, et al. Role of blood pressure in the development of congestive heart failure. The Framingham study. N Engl J Med. 1972;287:781–787(PubMed ID Number: 426273: No Abstract)
  29. Kannel WB, Feinleib M. Natural history of angina pectoris in the Framingham study. Prognosis and survival. Am J Cardiol. 1972;29:154–163(PubMed ID Number: 5058341: No Abstract)
  30. Kannel WB. Role of blood pressure in cardiovascular morbidity and mortality. Prog Cardiovasc Dis. 1974;17:5–24(PubMed ID Number: 4276031: No Abstract)
  31. Kannel WB, Abbott RD, Savage DD, et al. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med. 1982;306:1018–1022(PubMed ID Number: 7062992: Abstract)
  32. Parikh NI, Hwang SJ, Larson MG, et al. Parental occurrence of premature cardiovascular disease predicts increased coronary artery and abdominal aortic calcification in the Framingham Offspring and Third Generation cohorts. Circulation. 2007;116:1473–1481(Epub 2007 Sep 4)
  33. Haynes SG, Feinleib M. Women, work and coronary heart disease: prospective findings from the Framingham Heart study. Am J Public Health. 1980;70:133–141(PubMed ID Number: 7352607: Abstract)
  34. Keys A. A multivariate analysis of death and coronary heart disease. London, England: Harvard University Press; 1980;
  35. In:  Tunstall-Pedoe H editors. Multimedia Sourcebook. Geneva: World Health Organization; 2003;The Monograph is also available at the MONICA website http://www.ktl.fi/monica/public/monograph.html
  36. World Health Organization . The World Health Report 2002 Reducing Risks; Promoting Health Life. Geneva, Switzerland: World Health Organization; 2002;
  37. Yusuf S, Hawken S, Ounpuu S, et al., INTERHEART Study Investigators  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937–952
  38. World Health Organization . Global Health Risks; mortality and burden of disease attributable to selected major risks. Geneva, Switzerland: World Health Organization; 2009;
  39. Prevention of cardiovascular disease. Guidelines for assessment and management of cardiovascular risk. Geneva, Switzerland: World Health Organization; 2007;
  40. World Health Assembly . Global strategy for the prevention and control of noncommunicable diseases (NCDs). Geneva, Switzerland: World Health Organization; 2000;(WHA A53/14)
  41. World Health Organization . Prevention of recurrent heart attacks and strokes in low and middle income populations. Evidence-based recommendations for policy makers and health professionals. Geneva, Switzerland: World Health Organization; 2003;
  42. World Health Organization . Package of essential noncommunicable (PEN) disease interventions for primary health care in low resource settings. Geneva, Switzerland: World Health Organization; 2009;
  43. World Health Assembly . Action plan for the global strategy for the prevention and control of noncommunicable diseases (NCDs). Geneva, Switzerland: World Health Organization; 2008;(WHA A61/8)
  44. Conference of the parties to the WHO Framework Convention on Tobacco Control. Geneva: World Health Organization; 2002;http://www.who.int/gb/fctc/PDF/cop2/FCTC_COP2_17P-en.pdf
  45. Global strategy on diet, physical activity and health. Geneva: World Health Organization; 2004;
  46. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–1847
  47. Wilson PW, Castelli WP, Kannel WB. Coronary risk prediction in adults (the Framingham Heart Study). Am J Cardiol. 1987;59:91G–94G(PubMed ID Number: 3591674: Abstract)
  48. Brindle P. QRISK2 vs Framingham. Practitioner. 2008;252:42;(author reply 42)
  49. Lindholm LH, Mendis S. Prevention of cardiovascular disease in developing countries. Lancet. 2007;370:720–722
  50. Folsom AR, Chambless LE, Ballantyne CM, et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med. 2006;166:1368–1373
  51. Greenland P, O'Malley PG. When is a new prediction marker useful? A consideration of lipoprotein-associated phospholipase A2 and C-reactive protein for stroke risk. Arch Intern Med. 2005;165:2454–2456

 Statement of Conflict of Interest: see page 13.

PII: S0033-0620(10)00002-2

doi: 10.1016/j.pcad.2010.01.001

Progress in Cardiovascular Diseases
Volume 53, Issue 1 , Pages 10-14 , July 2010

Article Tools